Simplicity Wealth LLC acquired a new position in Ventyx Biosciences, Inc. (NASDAQ:VTYX – Free Report) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 29,405 shares of the company’s stock, valued at approximately $162,000.
Other large investors have also modified their holdings of the company. Tower Research Capital LLC TRC raised its position in shares of Ventyx Biosciences by 1,424.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 19,927 shares of the company’s stock worth $49,000 after purchasing an additional 18,620 shares during the last quarter. Federated Hermes Inc. acquired a new position in shares of Ventyx Biosciences during the 4th quarter worth about $50,000. Norden Group LLC acquired a new position in shares of Ventyx Biosciences during the 1st quarter worth about $59,000. Aigen Investment Management LP acquired a new position in shares of Ventyx Biosciences during the 4th quarter worth about $65,000. Finally, Jump Financial LLC acquired a new position in shares of Ventyx Biosciences during the 4th quarter worth about $72,000. Institutional investors and hedge funds own 97.88% of the company’s stock.
Ventyx Biosciences Stock Down 1.8 %
Shares of Ventyx Biosciences stock traded down $0.08 during mid-day trading on Friday, hitting $4.37. The stock had a trading volume of 341,647 shares, compared to its average volume of 913,055. The firm has a 50-day moving average of $4.98 and a two-hundred day moving average of $3.93. Ventyx Biosciences, Inc. has a 12-month low of $1.87 and a 12-month high of $40.58. The firm has a market cap of $308.09 million, a P/E ratio of -1.35 and a beta of 0.48.
Analyst Ratings Changes
Several research analysts recently weighed in on the stock. Oppenheimer upgraded shares of Ventyx Biosciences from a “market perform” rating to an “outperform” rating and set a $12.00 price target for the company in a research report on Tuesday, March 12th. Canaccord Genuity Group dropped their price objective on shares of Ventyx Biosciences from $16.00 to $15.00 and set a “buy” rating for the company in a research note on Wednesday, March 13th. Wells Fargo & Company raised shares of Ventyx Biosciences from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $7.00 to $16.00 in a research note on Tuesday, March 12th. Finally, Lifesci Capital raised shares of Ventyx Biosciences from a “market perform” rating to an “outperform” rating in a research note on Wednesday, February 28th. Four equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $21.75.
Read Our Latest Stock Analysis on VTYX
Ventyx Biosciences Company Profile
Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.
Further Reading
- Five stocks we like better than Ventyx Biosciences
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- MarketBeat Week in Review – 5/20 – 5/24
- Overbought Stocks Explained: Should You Trade Them?
- NASDAQ 100 vs. NASDAQ Composite: A Detailed Breakdown of NASDAQ
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- These 2 Retail Traders Favorites are Nearing Major Breakouts
Want to see what other hedge funds are holding VTYX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ventyx Biosciences, Inc. (NASDAQ:VTYX – Free Report).
Receive News & Ratings for Ventyx Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ventyx Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.